氨基肽酶N在肾细胞癌组织的表达及意义

Expression of aminopeptidase N and its significance in renal cell carcinoma

目的探讨氨基肽酶N(CD13)在肾细胞癌中的表达水平及其临床意义。方法应用免疫组织化学染色方法检测CD13在93例肾癌组织及其相应癌旁组织和远癌正常肾组织中的表达水平。运用χ2检验分析肿瘤组织中CD13表达与临床病理因素的关系。运用Kaplan Meier法分析肿瘤组织CD13与患者术后总生存时间的关系。结果 CD13在93例肾癌组织中阳性表达率为73.11%(68/93),在癌旁组织中阳性表达率为21.51%(20/93),在正常肾组织中阳性表达率为6.45%(6/93)。与癌旁组织和正常肾脏组织比较,肾癌组织中CD13的阳性表达率显著升高,差异有统计学意义(P<0.05)。进一步分析显示CD13表达与肾癌的分化程度、淋巴结转移、临床TNM分期等临床病理因素相关(P<0.05)。K-M生存曲线提示肿瘤CD13阳性表达的病例较阴性表达者生存率降低,差异具有统计学意义(P<0.05)。多因素COX逐步回归分析提示CD13是影响总体生存率预后的独立危险因素。结论 CD13在肾癌的发生和发展中可能发挥重要的作用,可作为肾癌临床诊断和判断预后的一项重要指标。

[ Objective ] To explore the expression and clinical significance ofaminopeptidase N （CD13） in renal cell carcinoma. [Methods] The CD13 expressions in the renal carcinoma tissue, corresponding paracancerous tissue and normal renal tissue specimens from 93 cases of renal carcinoma were detected by immunohistochemical staining. The correlations between CD13 expression and clinicopathological characteristics were analyzed by Chi-squared test and survival curves were generated according to the Kaplan Meier method. [Results] The positive rate of CD13 protein was 73.11%（68/93） in the renal carcinoma tissue, 21.51%（20/93） in the adjacent tumor tissue and 6.45% （6/93） in the normal renal tissue. The expression of CD13 was significantly up-regulated in the renal carcinoma with statistical dif- ferences （P 〈 0.05）. Statistical analysis revealed that CD13 expression was correlated with histological differentiation, lymph node metastasis and clinical stages in the renal carcinoma （P 〈 0.05）. The survival curves showed that the sur- vival rate was significantly lower in the patients with positive CD13 expression than in those with negative expression （P 〈 0.05）. Also, the multivariate COX proportional hazard model showed that CD13 expression was an independent predictor of overall survival （P 〈 0.05）. [ Conclusions ] CD13 plays a mutually promoting role in the progression and development of renal carcinoma and may be a diagnostic and prognostic indicator for renal carcinoma patients.